The microtubule-affecting drug paclitaxel has antiangiogenic activity

Dorina Belotti, Veronica Vergani, Teresa Drudis, Patrizia Borsotti, Maria Rosa Pitelli, Giuseppe Viale, Raffaella Giavazzi, Giulia Taraboletti

Research output: Contribution to journalArticlepeer-review


Endothelial cell migration is a critical event during angiogenesis, and inhibitors of cell motility can affect the angiogenic process. Paclitaxel (Taxol®), a microtubule-stabilizing antineoplastic cytotoxic drug, inhibits motility and invasiveness of several cell types. The aim of this study was to investigate the effect of paclitaxel on endothelial cell functions and on angiogenesis. In vivo, paclitaxel (20-28 mg/kg i.v.) significantly inhibited the angiogenic response induced by tumor cell supernatant embedded in a pellet of reconstituted basement membrane (Matrigel) injected s.c. into C57BL/6N mice. In vitro, paclitaxel inhibited endothelial cell proliferation, motility, invasiveness, and cord formation on Matrigel in a dose-dependent manner. The antiangiogenic activity of paclitaxel was not linked to its cytotoxicity, since inhibition of endothelial cell chemotaxis and invasiveness occurred at drug concentrations which did not affect endothelial cell proliferation. Another cytotoxic drug, cisplatin, that inhibited endothelial cell proliferation in vitro, did not affect angiogenesis in vivo. These data indicate that paclitaxel has a strong antiangiogenic activity, a property that might contribute to its antineoplastic activity in vivo.

Original languageEnglish
Pages (from-to)1843-1849
Number of pages7
JournalClinical Cancer Research
Issue number11
Publication statusPublished - Nov 1996

ASJC Scopus subject areas

  • Cancer Research
  • Oncology


Dive into the research topics of 'The microtubule-affecting drug paclitaxel has antiangiogenic activity'. Together they form a unique fingerprint.

Cite this